TB-500 Future Formulations & Pipeline: What's Coming for Thymosin Beta-4

HealthRX.com

No TB drug is in development; activity is regulatory

889 g/molMolecular weight of the 7-amino-acid TB-500 fragmentSource: fda.gov

Print or save as PDF

Key numbers

  • 2 mg to 15 mgVial size of research-use-only TB-500 powder sold online, alone or blended with BPC-157Source: fda.gov, as cited Nov 7, 2026
  • 50 microgram/mLTB-500 concentration in an in-vitro wound assay that did not induce fibroblast wound closureSource: fda.gov, as cited Nov 7, 2026
  • 889 g/molMolecular weight of the 7-amino-acid TB-500 fragmentSource: fda.gov, as cited Nov 7, 2026

See the public record for TB-500

  • What TB-500 is / Synthetic N-acetylated 7-amino-acid fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4, about 889 g/mol [1]
  • Human dosing data / FDA found no human dosing study, no human pharmacokinetic or pharmacodynamic data, no approved dose, and no pharmacy marketing a compounded TB-500 product [1]
  • Product actually sold / Research-use-only injectable powder in 2 mg to 15 mg vials, alone or blended with BPC-157 [1]
  • Human trials of TB-500 / None found by FDA in PubMed, Embase or ClinicalTrials.gov [1]
  • FDA position, July 2026 / Staff proposed that neither TB-500 free base nor TB-500 acetate be added to the pharmacy bulk-substances list [1]
  • Advisory vote / Pharmacy Compounding Advisory Committee voted in favor of listing on July 23, 2026; advice only [2][3]
  • HHS draft policy / Filed October 28, 2026, covering TB-500 acetate by subcutaneous or intramuscular injection; not an approval [3][4]
  • Sport status / WADA lists thymosin-beta4 and its derivatives including TB-500 in S2.3, prohibited at all times [5][6]

Is there a TB-500 pipeline at all?

A pipeline means a developer taking one molecule through formulation, animal testing and human trials. For TB-500, FDA found no human dosing study, no human pharmacokinetic or pharmacodynamic data, and no in-vivo animal wound-healing study [1].

TB-500 is a synthetic, N-acetylated 7-amino-acid fragment — residues 17 to 23 of the 43-amino-acid protein thymosin beta-4 — with a molecular weight of about 889 g/mol [1]. It is a common name, not an official drug name, and FDA found several salts and derivatives, including different active moieties, sold under it [1].

TB-500 is sold online as research-use-only injectable powder in vials of 2 mg to 15 mg, alone or blended with BPC-157 [1]. FDA found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1]. TB-500 also appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians [7][8][9].

What is actually moving: three regulatory events

FDA staff said no in July 2026

FDA's July 2026 briefing document recommended that neither TB-500 free base nor TB-500 acetate be added to the pharmacy bulk-substances list. The reasons given: the substance is not well characterized (inconsistent naming, no impurity, aggregate or endotoxin data), its historical use is unclear, there was no evidence of effectiveness for wound healing — the use FDA evaluated — there was no human data of any kind, injectable peptides carry an immunogenicity risk, and FDA-approved wound treatments already exist [1].

The same review found no USP or National Formulary monograph for TB-500, no FDA-approved drug containing it, no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1].

The advisory committee voted the other way

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee reviewed TB-500 free base and TB-500 acetate for the nominated use of wound healing, and voted in favor of adding it to the pharmacy bulk-substances list — against FDA staff's recommendation [2][3]. That vote is advice only and is not binding. TB-500 is not on the list, and adding it would take formal rulemaking [3].

The HHS draft enforcement policy

HHS filed a draft enforcement-discretion policy for six peptides — BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 — on October 28, 2026 (Federal Register document 2026-22192, publication scheduled for October 30, 2026, comments due two weeks after publication) [3][4]. It covers TB-500 acetate given by subcutaneous or intramuscular injection. HHS says it "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding with it if the policy's conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading "This is a compounded drug product. Not for resale." [3][4]

That draft is not an approval and does not put TB-500 on any list. The notice states that it "does not establish any rights for any person and is not binding on HHS or the public," and that HHS may revisit it, for example if a safety signal or product quality issue arises [3]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [3].

What a TB-500 formulation would still have to address

FDA's July 2026 review pointed to two gaps. On characterization, it faulted the naming and the data behind it — several salts and derivatives, including different active moieties, are sold under the same name, and there were no impurity, aggregate or endotoxin data [1]. On safety, FDA's stated concern for injectable TB-500 is immunogenicity, an immune reaction potentially amplified by peptide aggregation and peptide-related impurities [1].

The review described an in-vitro scratch-wound assay in which TB-500 at 50 microgram/mL did not induce wound closure in fibroblast cultures, while a shorter metabolite, N-acetylated LKKTE, did show activity in vitro [1]. Animal work indicates that TB-500 given subcutaneously or intraperitoneally reaches the bloodstream and is broken down into smaller peptides [1].

The thymosin beta-4 programs that do exist, and are not TB-500

Most of what gets described as a thymosin beta-4 pipeline is work on the full-length 43-amino-acid protein. It is a different molecule from the 7-amino-acid fragment, and its results do not show whether TB-500 works or is safe [1].

  • Eye drops (RGN-259). A phase 2 trial randomized 72 adults with moderate to severe dry eye to 0.1% thymosin beta-4 drops or placebo for 28 days. Neither primary endpoint — ocular discomfort or inferior corneal staining — differed significantly between groups, though several secondary endpoints did, including a 27% reduction in discomfort in the controlled-environment challenge at day 28 (P=0.0244). No adverse events were reported [10]. A separate, much smaller phase 2 trial treated 9 patients with severe dry eye (12 treated eyes versus 6 vehicle eyes) six times daily for 28 days; at day 56 ocular discomfort fell 35.1% and total corneal staining 59.1% versus vehicle [11].
  • Intravenous recombinant protein (NL005). A phase 1 study gave 54 healthy volunteers a single intravenous dose of recombinant human thymosin beta-4 at 0.05 to 25 microgram/kg across seven cohorts, and 30 volunteers received 0.5, 2 or 5 microgram/kg daily for 10 days. Adverse events were mild to moderate, with no dose-limiting toxicity or serious adverse events and no obvious accumulation [12].
  • After a heart attack. A randomized, placebo-controlled trial in 96 STEMI patients found infarct area was smaller at 90 days in the subgroup that received the first dose within 8 hours (n=43), but the difference across all 96 patients was not significant [13].

What is known about the product being sold now

Safety in humans is unknown [1]. FDA's adverse-event database search through March 26, 2025 retrieved no TB-500 reports, and its food and supplement complaint system (January 1, 2004 to March 10, 2025) retrieved two cases about a blended TB-500 and BPC-157 product with no safety assessment; FDA found no published case reports [1].

One case in FDA's BPC-157 review involved a 40-year-old woman who injected a research-purposes-only BPC-157 plus TB-500 product (5 mg/5 mg) subcutaneously twice daily and developed widespread skin hyperpigmentation and gum darkening within a week, which recurred when she tried the product again two weeks later. Because the product contained two peptides, FDA said it cannot tell whether either caused it [14].

WADA names "Thymosin-beta4 and its derivatives e.g. TB-500" in S2.3 of its Prohibited List, covering growth factors and growth factor modulators. It is prohibited at all times, in and out of competition, on the 2026 List in force since January 1, 2026 and on the 2027 List [5][6].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. What did FDA staff recommend in July 2026 about adding the peptide to the pharmacy bulk-substances list?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Questions worth asking

Choose the questions you want to keep

Is there a TB-500 product in development?
FDA's July 2026 review found no approved TB-500 product, no human dosing study, no human pharmacokinetic or pharmacodynamic data, and no article in which TB-500 was given to a person [1]. The activity around TB-500 is regulatory: an FDA staff recommendation against listing it, an advisory committee vote in favor on July 23, 2026, and a draft HHS enforcement-discretion policy filed in October 2026 [1][2][3].
Did the FDA advisory committee approve TB-500?
No. The Pharmacy Compounding Advisory Committee voted on July 23, 2026 in favor of adding TB-500 to the pharmacy bulk-substances list, against FDA staff's recommendation. That vote is advice only; TB-500 is not on the list and adding it would require formal rulemaking [2][3].
Does the HHS draft policy make compounded TB-500 legal?
No. The draft filed October 28, 2026 says HHS does not intend to take enforcement action against certain state-licensed pharmacies, federal facilities or licensed physicians compounding with TB-500 acetate for injection if its conditions are met. It is not an approval and does not put TB-500 on any list [3][4].
Do the thymosin beta-4 eye drop or heart trials apply to TB-500?
No. Those trials used recombinant full-length thymosin beta-4, a 43-amino-acid protein. TB-500 is a 7-amino-acid fragment of it, and results with the full-length protein do not show that TB-500 works or is safe [1].
What did FDA's review say about how well TB-500 is characterized?
FDA's July 2026 review said the substance is not well characterized: several salts and derivatives, including different active moieties, are sold under the same name, and the review found no impurity, aggregate or endotoxin data. It also cited unclear historical use and an immunogenicity risk for injected peptides [1].
Is TB-500 banned in sport?
Yes. WADA names thymosin-beta4 and its derivatives including TB-500 in S2.3 of its Prohibited List, prohibited at all times in and out of competition. It is on the 2026 List and stays on the 2027 List [5][6].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Is TB500 the same as Thymosin beta-4?

No. TB-500 is a 7-amino-acid fragment (residues 17 to 23) of thymosin beta-4, a 43-amino-acid protein, and it is a common name rather than an official drug name. Results from trials of the full-length protein do not show whether TB-500 works or is safe.

Is TB4 safe?

Safety in humans for TB-500 is unknown. FDA found no human dosing data and no published case reports. In a phase 1 study of the full-length recombinant protein, 54 healthy volunteers had mild to moderate adverse events with no serious adverse events, but those results do not transfer to TB-500.

Show all 14 referencesHide references
  1. U.S. Food and Drug Administration.
  2. U.S. Food and Drug Administration.
  3. Official web page.
  4. Official web page.
  5. World Anti-Doping Agency.
  6. World Anti-Doping Agency.
  7. U.S. Food and Drug Administration.
  8. U.S. Food and Drug Administration.
  9. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
  10. Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84.
  11. Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-6.
  12. Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.
  13. Zhang Y, Dong Q, Bian X, Qiao Z, Cui C, Yang N, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025;121(17):2747-2758.
  14. U.S. Food and Drug Administration.
Evidence overview for TB-500 Future Formulations & Pipeline: What's Coming for Thymosin Beta-4